ePrints

TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer

Lookup NU author(s): Dr Khaver Qureshi, Thomas Griffiths, Dr Mary Robinson, Dr James Roberts, Professor John LunecORCiD, Professor David Neal

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

To examine retrospectively the prognostic significance of TP53 immunoreactivity for both tumor response and patient survival in 83 patients with nonmetastatic muscle-invasive bladder cancer treated with a single transurethral resection (TUR) of tumor and combined cisplatin-based systemic chemotherapy followed by repeat TUR, paraffin-embedded sections of a bladder tumor obtained at TUR before chemotherapy (1 T2, 52 T3, and 30 T4) were immunostained for TP53 using monoclonal PAb1801 and DO-7 antibodies. For the entire cohort, TP53 immunopositivity (PAb1801 or DO-7) did not predict complete response (CR), complete or partial response (PR), progressive disease, or time to death from bladder cancer. There was a highly significant correlation between PAb1801 and DO-7 nuclear immunoreactivity (r = 0.8242; P < 0.0001). In 76 patients in which complete clinical data were available, tumor stage (T2/T3; P = 0.0499), CR and PR (P = 0.0016) and CR (P < 0.0001) were associated with patient survival. In a multivariate model, CR (P < 0.0001) was the only independent predictor of improved survival. In complete responders, neither TP53 immunostaining nor clinicopathological factors stratified patients into prognostic groups. However, in the subset of patients (n = 38) who were chemoresistant (PR or progressive disease), improved survival was associated with ≥20% TP53 immunoreactivity (PAb1801; P = 0.0191) and tumor stage (T2/T3; P = 0.0358). TP53 immunopositivity (PAb1801 or DO-7) did not predict overall survival or response to systemic chemotherapy in patients with nonmetastatic but predominantly clinical stage ≥T3 bladder cancer, but it had prognostic significance within the chemoresistant subgroup.

Publication metadata

Author(s): Qureshi, K., Griffiths, T., Robinson, M., Marsh, C., Roberts, J., Hall, R., Lunec, J., Neal, D.E.

Publication type: Article

Publication status: Published

Journal: Clinical Cancer Research

Year: 1999

Volume: 5

Issue: 11

Pages: 3500-3507

Print publication date: 01/11/1999

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

PubMed id: 10589764

Share